Jonathan Schapiro

9.0k total citations · 1 hit paper
83 papers, 5.9k citations indexed

About

Jonathan Schapiro is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Jonathan Schapiro has authored 83 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Infectious Diseases, 62 papers in Virology and 16 papers in Hepatology. Recurrent topics in Jonathan Schapiro's work include HIV/AIDS drug development and treatment (65 papers), HIV Research and Treatment (62 papers) and HIV/AIDS Research and Interventions (46 papers). Jonathan Schapiro is often cited by papers focused on HIV/AIDS drug development and treatment (65 papers), HIV Research and Treatment (62 papers) and HIV/AIDS Research and Interventions (46 papers). Jonathan Schapiro collaborates with scholars based in United States, Israel and United Kingdom. Jonathan Schapiro's co-authors include Robert W. Shafer, Daniel R. Kuritzkes, Deenan Pillay, Bonaventura Clotet, Françoise Brun‐Vézinet, Victoria A. Johnson, Charles A. Boucher, Douglas D. Richman, Soo‐Yon Rhee and Mark A. Winters and has published in prestigious journals such as Nature Genetics, Annals of Internal Medicine and The Journal of Immunology.

In The Last Decade

Jonathan Schapiro

81 papers receiving 5.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

2009 731 citations Ricardo Camacho, Dan Oţelea et al. PLoS ONE profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jonathan Schapiro	5.0k	4.8k	795	516	479	83	5.9k
Hiroyuki Gatanaga	2.8k 0.6×	2.1k 0.4×	1.5k 1.9×	623 1.2×	499 1.0×	252	4.8k
Jacob Lalezari	3.4k 0.7×	3.0k 0.6×	3.5k 4.4×	676 1.3×	1.4k 2.9×	138	6.9k
Brian P. Kearney	3.9k 0.8×	2.4k 0.5×	1.1k 1.4×	556 1.1×	698 1.5×	93	5.1k
Peter Ruane	3.4k 0.7×	2.2k 0.5×	1.7k 2.1×	499 1.0×	940 2.0×	78	4.7k
Miklos Salgo	2.1k 0.4×	1.9k 0.4×	539 0.7×	469 0.9×	238 0.5×	53	3.2k
Zabrina L. Brumme	2.9k 0.6×	3.9k 0.8×	880 1.1×	884 1.7×	239 0.5×	176	5.3k
Schlomo Staszewski	6.1k 1.2×	5.1k 1.1×	1.5k 1.8×	384 0.7×	378 0.8×	115	7.3k
Douglas L. Mayers	2.9k 0.6×	2.5k 0.5×	802 1.0×	335 0.6×	412 0.9×	90	3.9k
Patricia Barditch‐Crovo	1.7k 0.4×	2.0k 0.4×	635 0.8×	320 0.6×	131 0.3×	27	3.0k
Jay A. Grobler	2.6k 0.5×	1.9k 0.4×	750 0.9×	1.4k 2.7×	372 0.8×	61	3.7k

Countries citing papers authored by Jonathan Schapiro

Since Specialization

Citations

This map shows the geographic impact of Jonathan Schapiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Schapiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Schapiro more than expected).

Fields of papers citing papers by Jonathan Schapiro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Schapiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Schapiro. The network helps show where Jonathan Schapiro may publish in the future.

Co-authorship network of co-authors of Jonathan Schapiro

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Schapiro. A scholar is included among the top collaborators of Jonathan Schapiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Schapiro. Jonathan Schapiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Batterham, Rachel L., Roger Bedimo, Ricardo Sobhie Diaz, et al.. (2024). Cardiometabolic health in people with HIV: expert consensus review. Journal of Antimicrobial Chemotherapy. 79(6). 1218–1233. 7 indexed citations

Levy‐Mendelovich, Sarina, Christopher Walsh, Jonathan Schapiro, et al.. (2023). A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?. Haemophilia. 29(3). 784–789. 1 indexed citations

Rhee, Soo‐Yon, Jonathan Schapiro, Francesco Saladini, et al.. (2023). Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance. AIDS Research and Therapy. 20(1). 8–8. 3 indexed citations

Paredes, Roger, Philip L. Tzou, Gert U. van Zyl, et al.. (2017). Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS ONE. 12(7). e0181357–e0181357. 30 indexed citations

Zolfo, María, Jonathan Schapiro, Olivier Koole, et al.. (2010). Genotypic Impact of Prolonged Detectable HIV Type 1 RNA Viral Load after HAART Failure in a CRF01_AE-Infected Cohort. AIDS Research and Human Retroviruses. 27(7). 727–735. 14 indexed citations

Llibre, Josep M., Anna Bonjoch, Eugènia Negredo, et al.. (2008). Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study. HIV Medicine. 9(7). 508–513. 11 indexed citations

Maor‬‏, ‪Yasmin, Jonathan Schapiro, Dalia Bashari, et al.. (2008). Treatment of hepatitis C in patients with haemophilia – the Israeli National Hemophilia Center experience. Haemophilia. 14(2). 336–342. 7 indexed citations

Gruttola, Victor De, Charles Flexner, Jonathan Schapiro, et al.. (2006). Drug Development Strategies for Salvage Therapy: Conflicts and Solutions. AIDS Research and Human Retroviruses. 22(11). 1106–1109. 8 indexed citations

Averbuch, Diana, Jonathan Schapiro, E. Randall Lanier, et al.. (2006). Diminished Selection for Thymidine-Analog Mutations Associated With the Presence of M184V in Ethiopian Children Infected With HIV Subtype C Receiving Lamivudine-Containing Therapy. The Pediatric Infectious Disease Journal. 25(11). 1049–1056. 16 indexed citations

10.

Rhee, Soo‐Yon, Rami Kantor, David Katzenstein, et al.. (2006). HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 20(5). 643–651. 72 indexed citations

11.

Rhee, Soo‐Yon, W. Jeffrey Fessel, Andrew Zolopa, et al.. (2005). HIV‐1 Protease and Reverse‐Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug‐Resistance Surveillance. The Journal of Infectious Diseases. 192(3). 456–465. 94 indexed citations

12.

Shafer, Robert W. & Jonathan Schapiro. (2005). Drug resistance and antiretroviral drug development. Journal of Antimicrobial Chemotherapy. 55(6). 817–820. 13 indexed citations

13.

Cua, Éric, J. Durant, Ronan Boulmé, et al.. (2002). Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients. HIV Clinical Trials. 3(1). 36–44. 14 indexed citations

14.

Gray, Clive M., Jody Lawrence, Erik A. Ranheim, et al.. (2000). Highly Active Antiretroviral Therapy Results in HIV Type 1 Suppression in Lymph Nodes, Increased Pools of Naive T Cells, Decreased Pools of Activated T Cells, and Diminished Frequencies of Peripheral Activated HIV Type 1-Specific CD8 ⁺ T Cells. AIDS Research and Human Retroviruses. 16(14). 1357–1369. 19 indexed citations

15.

Sevin, Anne, Victor DeGruttola, Monique Nijhuis, et al.. (2000). Methods for Investigation of the Relationship between Drug‐Susceptibility Phenotype and Human Immunodeficiency Virus Type 1 Genotype with Applications to AIDS Clinical Trials Group 333. The Journal of Infectious Diseases. 182(1). 59–67. 67 indexed citations

16.

Heim, M., et al.. (2000). Drug‐induced and traumatic nail problems in the haemophilias. Haemophilia. 6(3). 191–194. 6 indexed citations

17.

Durant, J., Philippe Clevenbergh, R. Garraffo, et al.. (2000). Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 14(10). 1333–1339. 182 indexed citations

18.

Schapiro, Jonathan, Mark A. Winters, Jody Lawrence, & Thomas C. Merigan. (1999). Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS. 13(3). 359–365. 41 indexed citations

19.

Schapiro, Jonathan, Jody Lawrence, Roberto F. Speck, et al.. (1999). Resistance Mutations to Zidovudine and Saquinavir in Patients Receiving Zidovudine plus Saquinavir or Zidovudine and Zalcitabine plus Saquinavir in AIDS Clinical Trials Group 229. The Journal of Infectious Diseases. 179(1). 249–253. 9 indexed citations

20.

Lawrence, Jody, Jonathan Schapiro, Mark A. Winters, et al.. (1999). Clinical Resistance Patterns and Responses to Two Sequential Protease Inhibitor Regimens in Saquinavir and Reverse Transcriptase Inhibitor–Experienced Persons. The Journal of Infectious Diseases. 179(6). 1356–1364. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact